Skip to main content
Premium Trial:

Request an Annual Quote

Epigenomics Closes 21M Series C Round

NEW YORK, April 3 - Epigenomics has closed a Series C round of financing worth €21 million, or around $ 22.5 million, the company said today.


This third round brings to €56 million the total capital raised by the DNA methylation firm since it was created in 1998. Epigenomics said it will use the funds to further develop its diagnostic products in cancer, as well as its pharmacodiagnostic and research products.


New investor the Wellcome Trust Limited and all existing VC investors--3i Group, Abingworth, Deutsche Venture Capital DVC, MPM Capital, and tbg--participated in the round.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.